Connect with SHL Group at Outsourced Pharma 2017 San Francisco

Press Release 201710

SHL Group is excited to announce our participation as an exhibitor at Outsourced Pharma 2017 in San Francisco, CA from October 17-18. SHL will show a wide range of capabilities assembling, labeling, and packaging for autoinjectors and pen injectors at Booth 63. We look forward to welcoming pharma’s best and brightest and helping them meet their clinical and commercial needs, from innovative device design through to world-class device assembly, labeling, and packaging.

The rapid growth of the biologics and biosimilars market has created a significant demand for self-injection devices for the treatment of chronic indications. Biologics are often prescribed for chronic conditions where patients need frequent injections and are often required to self-administer medications at home. Biologic drug products have been growing significantly in market share the last few years. Currently, the number of biotechnology products under development exceeds that of conventional drug products. With the increased market share of biologic drugs and the growth in the biosimilar market, SHL is planning for the future with new, innovative drug delivery devices focused on the patient’s needs and building an infrastructure to streamline the development process.

To learn more about our injection devices, visit us at Booth 63 at the Hyatt Regency San Francisco Airport.

About SHL

SHL Group is a world-leading solutions provider in the design, development, and manufacturing of advanced drug delivery devices such as autoinjectors, pen injectors and advanced inhaler systems. We also offer core competencies and services in the fields of medtech and patient care solutions. With locations in Taiwan, Switzerland, Sweden, China and the US, our experienced engineers and designers develop product enhancements as well as breakthrough drug delivery and patient care solutions for pharma and biotech clients globally. Significant investment in R&D has enhanced our broad pipeline of next-generation drug delivery systems that support ongoing innovations in drug development and digital healthcare. This includes advanced reusable and disposable injectors that can accommodate high volume and high viscosities and can be enhanced through digital implementations.

With over 4,800 employees worldwide, SHL Group consists of several distinct group companies:

SHL Medical designs, develops and manufactures advanced drug delivery devices, as well as provides final assembly, labeling and packaging services for leading pharmaceutical and biotech companies across the globe.

SHL Healthcare develops and manufactures equipment solutions for home, hospital and long term care use.

SHL Technologies provides contract manufacturing and engineering services for the production of complex medtech and industrial products.

For additional information, visit

Media contact:


Related News